Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pfizer Signs Cancer Candidate To Clovis
by Rick Mullin
June 13, 2011
| A version of this story appeared in
Volume 89, Issue 24
Clovis Oncology and Pfizer have signed an agreement under which Clovis will assume responsibility for Pfizer’s oral and intravenous poly(ADP-ribose) polymerase (PARP) inhibitor, PF-01367338, a small-molecule therapeutic currently in Phase I and II development programs for solid tumors. Pfizer will receive an undisclosed equity stake in Clovis and milestone payments of up to $255 million. “Clovis Oncology is the ideal choice to continue the development and commercialization of PF-01367338,” says Garry Nicholson, president and general manager of Pfizer Oncology.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter